Slate Bio
Charlottesville, US · Founded 2020 · Delaware corporation · 4 employees on LinkedIn · 2 known investors
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
Founders & leadership
RC
Robert CreedenNamed on SEC filing
KW
Kurt WoerpelNamed on SEC filing
AJ
Andrew J KrouseNamed on SEC filing
Board
KS
Investors · 2
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 2 rounds · 2020–2022
▶$2.8MraisedMay 2023 · 9 investors · Other Health CareRule 506(b)
▶$2.8MraisedMay 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KrouseExecutive Officer, Director
- Kurt WoerpelExecutive Officer
- Robert CreedenDirector
- Kyparissia SirinakisDirector
- Brian GallagherDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2MraisedJun 2021 · 10 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CreedenDirector
- Kurt WoerpelExecutive Officer
- Kyparissia SirinakisDirector
- Andrew J KrouseExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Slate Medicines4 shared keywordsSlate Medicines is a clinical-stage biotechnology company. The page profiles an executive but provides limited detail on the company's specific therapeutic focus.
Milestone Pharmaceuticals4 shared keywordsMilestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
Talus Bio4 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Forbion4 shared keywordsForbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health. It integrates ESG principles into its investments, targeting patient impact, societal benefits, and sustainability.
AltaThera Pharmaceuticals3 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
Companies competing with Slate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Slate Bio do?
- Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
- Who are Slate Bio's investors?
- Slate Bio's investors include Epidarex Capital, VTC Ventures.
- How much funding has Slate Bio raised?
- Slate Bio has disclosed $4.8M raised across 2 rounds.
- Where is Slate Bio headquartered?
- Slate Bio is headquartered in Charlottesville, US.